Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$13.5MCash on Hand
13.6mo Cash Runway
Follow RTSN by emailGet an email when RTSN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RTSN, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Oct 23, 2026 ·
Leadership Retension appointed Robert Wong as Vice President, Chief Accounting Officer, effective November 2, 2026. His offer letter provides a $360,000 base salary, a 30% target bonus, a $20,000 sign-on bonus, and an option for 25,000 shares. Form 8-K · SEC filing
Oct 13, 2026 ·
Retension Pharmaceuticals closed its initial public offering on October 13, 2026. Its Third Amended and Restated Certificate of Incorporation was filed in Delaware on October 9, 2026, and its Amended and Restated Bylaws took effect before the closing. Form 8-K · SEC filing
Oct 9, 2026 ·
Financing Retension Pharmaceuticals priced an initial public offering of 3,750,000 shares of common stock at $12.00 per share, for total proceeds of $45,000,000 before underwriting discounts. Shares will list on Nasdaq under RTSN, and underwriters hold a 30-day option for 562,500 additional shares. Form 424B4 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2027 · Phase 2 · Recruiting · A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
RTSN holds $13.5M in cash and short-term investments and burns about $3M/quarter from operations,
an estimated runway of 13.6 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RTSN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.